Last reviewed · How we verify

Placebo, docetaxel — Competitive Intelligence Brief

Placebo, docetaxel (Placebo, docetaxel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane; microtubule stabilizer. Area: Oncology.

phase 3 Taxane; microtubule stabilizer Beta-tubulin Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo, docetaxel (Placebo, docetaxel) — Akeso. Docetaxel is a microtubule-stabilizing agent that prevents microtubule disassembly, leading to cell cycle arrest and apoptosis in cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Placebo, docetaxel TARGET Placebo, docetaxel Akeso phase 3 Taxane; microtubule stabilizer Beta-tubulin
Colchicine Pill Colchicine Pill Brigham and Women's Hospital marketed Microtubule inhibitor / Anti-inflammatory agent Beta-tubulin
Abraxane (Maintenance) Abraxane (Maintenance) Celgene phase 3 Microtubule stabilizer (taxane) Beta-tubulin / microtubules
Carboplatin+Paclitaxel Carboplatin+Paclitaxel AstraZeneca phase 3 Chemotherapy combination (platinum agent + taxane) DNA (carboplatin); beta-tubulin (paclitaxel)
Docetaxel, Cisplatin Docetaxel, Cisplatin Samsung Medical Center phase 3 Chemotherapy combination (taxane + platinum agent) Beta-tubulin (docetaxel); DNA (cisplatin)
Cisplatin and Docetaxel Cisplatin and Docetaxel Swiss Cancer Institute phase 3 Chemotherapy combination (platinum agent + taxane) DNA (cisplatin); beta-tubulin (docetaxel)
similar placebo to mebendazole similar placebo to mebendazole Swiss Tropical & Public Health Institute phase 3 Anthelmintic Beta-tubulin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane; microtubule stabilizer class)

  1. Sanofi · 2 drugs in this class
  2. Aravive, Inc. · 1 drug in this class
  3. Athenex, Inc. · 1 drug in this class
  4. Barts & The London NHS Trust · 1 drug in this class
  5. BeyondSpring Pharmaceuticals Inc. · 1 drug in this class
  6. Bio-Thera Solutions · 1 drug in this class
  7. Dai, Guanghai · 1 drug in this class
  8. Fujian Medical University · 1 drug in this class
  9. Guangzhou Double Bioproducts Co., Ltd · 1 drug in this class
  10. H. Lee Moffitt Cancer Center and Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo, docetaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-docetaxel. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: